Coenzyme Q10 and oxidative imbalance in Down syndrome: Biochemical and clinical aspects

BioFactors

Volumn 32, Issue 1-4, 2008, Pages 161-167

  Tiano, L ^a   Padella, L ^a   Carnevali, P ^a   Gabrielli, O ^a   Bruge, F ^a   Principi, F ^a   Littarru, G P ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; UBIDECARENONE; URIC ACID; DRUG DERIVATIVE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DOWN SYNDROME; HUMAN; LYMPHOCYTE; OXIDATIVE STRESS; PEDIATRICS; PRIORITY JOURNAL; THROMBOCYTE; ARTICLE; BLOOD; DRUG EFFECT; METABOLISM; PRESCHOOL CHILD;

ALLANTOIN; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; OXIDATIVE STRESS; UBIQUINONE; URIC ACID;

EID: 58149385696     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520320119     Document Type: Conference Paper

References (21)

1. O.I. Aruoma, J.P. Spencer and N. Mahmood, Protection against oxidative damage and cell death by the natural antioxidant ergothioneine, Food Chem Toxicol 37 (1999), 1043-1053.
2. B.W. Brooksbank and R. Balazs, Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain, Brain Res 318 (1984), 37-44.
3. G.T. Capone, Down Syndrome: Advances in Molecular Biology and the Neurosciences, Developmental and Behavioral Pediatrics 22(1) (2001).
4. J.B. de Hann, B. Susil, M. Pritchard and I. Kola, An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the "gene dosage effect" hypothesis, J Neural Transm Supp 67 (2003), 67-83.
5. G.K. Glantzounis, E.C. Tsimpyiannis, A.M. Kappas and D.A. Galaris, Uric acid and oxidative stress, Curr Pharm Des 11 (2005), 4145-4151.
6. T. Gulesserian, R. Seidl, R. Hardmeier, N. Cairns and G. Lubec, Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome, J Investig Med 49 (2001), 41-46.
7. S.H. Kim, M. Fountoulakis, M. Dierssen and G. Lubec, Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains, J Neural Transm Suppl 61 (2001), 109-116.
8. C.M. Li, M. Guo, M. Salas, N. Schupf, W. Silverman, W.B. Zigman, S. Husain, D. Warburton, H. Thaker and B. Tycko, Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21, BMC Med Genet 15 (2006), 7-24.
9. I.T. Lott, E. Head, E. Doran and J. Busciglio, Beta-amyloid, oxidative stress and down syndrome, Curr Alzheimer Res 3 (2006), 521-528.
10. 10 absorption and tolerance in children with Down syndrome: a dose-ranging trial, Pediatr Neurol 35 (2006), 30-37.
11. N.J. Miller, C. Rice-Evans, M.J. Davies, V. Gopinathan and A. Milner, A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates, Clin Sci 84 (1993), 407-412.
12. M. Pogribna, S. Melnyk, I. Pogribny, A. Chango, P. Yi and S.J. James, Homocysteine metabolism in children with Down syndrome: in vitro modulation, Am J Hum Genet 69 (2001), 88-95.
13. J. Roper Randall and H. Reeves Roger, Understanding the Basis for Down Syndrome Phenotypes, PLoS Genetics 2(3) (March 2006).
14. K. Sekine, N. Ota, M. Nishii, T. Uetake and ZM. Shimadzu, Estimation of plasma and saliva levels of coenzyme Q10 and influence of oral supplementation, BioFactors 25 (2005), 205-211.
15. G.L. Squadrito, R. Cueto, A.E. Splenser, A. Valavanidis, H. Zhang, R.M. Uppu and W.A. Pryor, Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid, Arch Biochem Biophys 376 (2000), 333-337.
16. K. Subba Rao, Mechanism of disease: DNA repair defects and neurological disease, Nat Clin Pract Neuro 3 (2007), 162-172.
17. Y.S. Suzuki, H.J. Forman and A. Sevanian, Oxidants as stimulators of signal transduction, Fr Radic Biol Med 22 (1997), 269-285.
18. L. Tiano, G.P. Littarru, F. Principi, M. Orlandi, L. Santoro, P. Carnevali and O, Gabrielli, Assessment of DNA damage in Down Syndrome patients by means of a new, optimised single cell gel electrophoresis technique, Biofactors 25 (2005), 187-195.
19. 10 inmitigating oxidative DNA damage in DS patients, a double blind randomized controlled trial, 2008, Submitted.
20. 10 ratio as a possible marker of increased risk for atherosclerosis, Biofactors 9 (1999), 231-240.
21. I. Zitnanova, P. Korytar, O.I. Aruoma, M. Sustrova, I. Garaiova, J. Muchovà, T. Kalnovicovà, S. Pueschel and Z. Durackova, Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta 341 (2004), 139-146.